This review highlights advances in the primary and secondary prevention of cardiovascular disease (CVD) in women in the preceding 12 months.
INTRODUCTION
Cardiovascular disease (CVD) remains the leading cause of death of women and men in the United States and around the world, despite the evolving knowledge of causative factors, available guidelines for primary and secondary prevention, and recent treatment advances generated from new technologies and medical sciences [1, 2] . Annual deaths from CVD among women have surpassed the rate of CVD deaths among men since the early 1980s [3] . CVD mortality rates among women have decreased since 2000, in part due to secondary prevention strategies, improvement in management of disease, and reduction in risk factors for CVD [4] . The overall incidence of CVD in women has reached a plateau; however, CVD in young women is on the rise [5] . Rising obesity rates among women aged 35-54 years may be exerting a direct effect on the increasing mortality rates of this subset of women in the US; this rise is disconcerting after a trend over the previous 40 years of declining mortality in this group [4] . Taken together, these patterns of morbidity and mortality in women call us to action to determine how we can do better at preventing the development and progression of CVD in women of all ages.
The importance of primary prevention of CVD in women is underscored by the prevalence of CVD and CVD risk factors among women in the United States, including high rates of obesity and smoking among young women [4] , high prevalence of hypertension among women 65 years of age and older, and less awareness of high cholesterol levels among women of all ages [3] . The case for secondary prevention of CVD can easily be made [6] from statistics revealing the adverse prognostic impact of excess body weight and abdominal obesity in persons with CVD, and the mortality rate among women following coronary events -26% of women at least 45 years (vs. 19% for men) within 1 year after event [3] . The good news is that a majority of causes of and risk factors for CVD and CVD progression are known and most are modifiable [7] . Renewed attention was drawn to the primary and secondary prevention of CVD in women following the publication of updated guidelines by the American Heart Association (AHA) for the prevention of CVD in women in January 2011 [8] . To address the issue of how we can do better in primary and secondary prevention of CVD in women, we undertook a review of the relevant, recent published literature. The purpose of this review was to identify, from studies that were published in the past 12 months, perspectives and new data to inform future efforts for primary and secondary prevention of CVD in women.
Methods
Electronic searches identified studies published between April 2011 and April 2012 related to prevention of CVD in women. To limit the scope of this study, the search strategy focused on primary and secondary prevention of CVD or coronary heart disease (CHD) in women. Stroke, peripheral vascular disease (PVD), diabetes and other cardiovascular conditions were secondary and incidental to this review, as were nonprevention related treatments of CVD, and venous thromboembolism and hypercoagulability states in pregnancy. Publications were selected for inclusion whether CVD prevention in women was the primary focus, or whether the identified article provided new information, perspectives or strategies relevant to prevention of CVD among women. Works identified included original research, reviews, editorials, guidelines and opinion articles. Excluded were small studies that were potentially underpowered or lacked broad generalizability.
REVIEW OF PUBLICATIONS
A mix of expert opinions, systematic and comprehensive reviews, and new evidence from original research were reviewed to identify promising strategies for the prevention of CVD in women. These works were examined in context of the state of the science as captured in national guidelines, such as: the 2011 AHA statement on the value of primordial and primary prevention of CVD [9] ; the AHA/American College of Cardiology Foundation (ACCF) 2011 update of the guideline for secondary prevention and risk reduction [6] ; the 2010 ACCF/ AHA guidelines for CVD risk in asymptomatic adults [10] ; and the 2011 AHA update of the women's effectiveness-based guideline for CVD prevention [8] . The nonoriginal works and expert opinions, and the original research and review articles, were reviewed separately. Highlights of these publications are briefly elaborated in Table 1 .
Nonoriginal works and expert opinions
Strategies relevant to the prevention of CHD in women were included in the published findings of the Minnesota Women's Heart Summit [11 && ] and in the publication of the 'Bold Ideas' generated from the Summit, which revisited the ongoing conundrum of preventing CVD in women [12 & ]. A significant number of other articles were published in the past year in which authors evaluated CVD screening and education efforts, debated the adequacy of CVD management and prevention in women (versus men), translated guidelines into practice, and analyzed current practice and related research in efforts to determine what is working and what is not working, and to identify future directions. Future strategies to reduce CVD morbidity and mortality in women were also evaluated [12 & ,13-34].
KEY POINTS
The incidence of CVD in women has leveled; however, CVD in young women is on the rise and women still lack awareness of risks and are often less adherent to taking prescribed medications than men.
Research reaffirms the importance of preventive therapies in both primary and secondary prevention for improved health outcomes.
Clinic level strategies (i.e. identification of at risk and high risk women and outreach) and public health strategies (e.g. improving access to healthy foods and opportunities for physical activity) are needed to address lifestyle and clinical risks.
Women's care (including OB/GYN) has an important role in reducing disparities in outcomes of CVD for women, particularly among populations of reproductive age. 
Original research, guidelines and reviews
Next, original research studies, meta-analyses, and systematic or high-quality focused reviews were examined. Articles were organized into four sections on the basis of their content, including screening and assessment; awareness and education; lifestyle; and preventive therapies.
Screening and assessment
Screening is necessary to identify women with risk factors for CVD to provide further assessment and medical management. Limited research was conducted in this area in the past 12 months. Of the research conducted, key focus areas were on what to measure, whether women were receiving recommended measures, and the importance of screening for depression. Rheaume et al. [35] report decreases in cardiorespiratory fitness and increases in visceral adiposity in a 6-year observational study. They advocate for measurements of waist circumference in the clinical environment and encourage clinicians to discuss physical activity in regular patient-provider encounters. Using National Health Interview Survey data, Robbins et al. [36] examined prevalence estimates for self-reported blood pressure (BP) and cholesterol screenings calculated for 4 837 women, finding that most women received BP screening, but many were not screened for cholesterol levels. From a systematic review of literature, Robbins et al. [37] conclude that inconsistencies in recommendations for cholesterol screening in this population may be responsible for the low screening rates.
Psychosocial factors related to CVD incidence, progression of disease and disease outcomes for women have recently received investigative attention. In their review article, Doering and Eastwood [38 & ] concluded that sufficient evidence of the association of anxiety and depression with CVD exists to warrant alerting clinicians to the heightened risk of depression and anxiety in women with diagnosed CVD. They recommended that more investigation be done to establish the effectiveness of routine inpatient screening for depression, to evaluate collaborative treatments for those who screen positive, and to determine if gender differences persist in screening results. Providers are encouraged to make referrals for treatment.
Awareness and education
Awareness of risk and education to increase knowledge and motivation to reduce risk among women to prevent CVD is important. Galbraith et al. [39] analyzed data from a random sampling of US women to test women's knowledge of CVD risk factors and to describe psychosocial barriers that prevented women from recognizing and acting on these risks. They found that women more than 45 years who were worried and knowledgeable were motivated to reduce risk. Results of a systematic review of large trials designed to test the effectiveness of primary health risk factor education and CVD risk reduction in rural populations concluded that current educational approaches to reduce CVD risk in rural communities had marginal effects [40] . More well-designed randomized controlled trials documenting the timing, intensity and duration of interventions and economic evaluations of the costs associated with the development and delivery of the interventions are needed. Trials that address these issues can assist health professionals in making informed decisions about what interventions to implement in order to most effectively reduce CVD risks.
Screening and education to raise awareness and motivate women to promote health behavior change were also examined. One publication specifically addressed women's awareness of CVD and the role of risk screening in order to provide associated risk factor education [41] . Giardina et al. [41] reported results from a study that targeted women at high risk for CHD with the goal of providing facts to help women recognize cardiac emergencies. In their study, fewer participants with high Framingham risk or with metabolic syndrome knew the leading cause of death or knew the signs and symptoms of a heart attack and the need to call 911. Investigators highlight the importance of culturally competent health education materials, and the need to provide repeated and sustained information to the population about CHD, the signs and symptoms of a heart attack and the importance of calling 911.
Lifestyle
The potential impact that making behavioral changes to improve lifestyle habits can have on health is substantial, conferring benefits for both primary and secondary prevention [7] . This past year, studies reported reductions in CVD morbidity and mortality resulting from adherence to healthy lifestyles reported that heart healthy lifestyle habits developed as a youth contribute to low CVD risk profiles of men and women in middle age [43 && ]; this was true for each sex-race group.
Behavior change may work alone or behavioral changes in combination may work together. Korhonen et al. [44] addressed multiple risk factors (smoking and sedentary lifestyle) in a study combining smoking cessation with an exercise program. They demonstrated that tobacco use could be reduced and exercise increased to benefit cardiorespiratory fitness while also improving CVD biomarkers and risk profiles in sedentary women. However, despite the positive benefits and decreased mortality associated with healthy behaviors, little progress has been made in improving health behaviors [45 && ]. Culturally competent lifestyle programs are also needed. New research in this area did show some promising results. An intervention study targeted African-American women, a high-risk group, to increase physical activity using ethnically relevant lifestyle strategies to achieve risk reduction [46] . In this trial, a comprehensive lifestyle behavioral program improved leisure time activity and reduced dietary fat intake; however, how that translated into reduced risk or incidence of CVD was not reported [46] .
Preventive therapies
Multifactorial treatment of CVD risks continues to be emphasized. The importance of prescribing medications based on risk and titrating medications to goal achievement is critical to achieve individual and public health goals. The use and dosing of statins for primary prevention of CVD continued to remain controversial following the publication of a systematic review [47] . When statins are used for primary prevention, it is important to evaluate the lifetime risk of CVD for each individual and weigh the risks and benefits of prescribing a statin for those individuals [19] . Aspirin use in women for primary prevention continues to be evaluated and discussed. In a recent study, aspirin failed to improve CVD outcomes in women [48] .
Less controversy exists for secondary prevention. Aspirin, hypertension medications and statins for dyslipidemia have been demonstrated to be effective strategies. Preventive therapies reduce CVD progression and CVD events and improve outcomes [49, 50, 51 && ]. However, preventive therapies for secondary prevention are often prescribed in conjunction with invasive treatments and women, compared with men, receive these treatments less often [50] . Symptomatic women also often received antithrombotic agents and lipid-lowering agents less frequently than men; however, in the Reduction of Atherothrombosis for Continued Health (REACH) registry there were no differences in primary outcomes in 2-year follow up of myocardial infarction, stroke and death [51 && ]. Medication adherence is also an important consideration as women are less likely to be adherent. The results of a large retrospective study of adherence to statins examined the medication possession ratio over 12 months as well as CVD hospitalizations and cost savings for the subsequent 18 months [52] . Statin adherence was associated with reductions in subsequent total healthcare costs and CVD hospitalizations. Thus, it is important to ask women how often they take their medications and to address barriers to taking them (e.g. side effects, cost).
Highlights
The most interesting and important work published on 'how we can do better' following the AHA guidelines on CVD prevention in women [8] ] point out the trends in mortality in the United States; healthy behaviors or a healthy lifestyle are associated with decreased CVD risks and mortality, but report that little progress has been made in developing or improving these behaviors amongst our society. According to Wenger [14] , defining a woman's risk status and then improving adherence to preventive lifestyle behaviors is the most effective way to lower CVD in women. Addressing disparities in invasive therapies offered to women compared with men, and the lack of invasive therapies available to disadvantaged women, is also important [50] .
Despite the high potential of primary care and women's care providers to reach women to screen for risk and treat risk factors; McSweeney et al. [28] describe the general lack of awareness of OB/GYN providers of CVD risk in women (i.e. lack of awareness of national guidelines). They assert that, although there are time constraints in practice, they should be asking women about three things: smoking status, weight gain and activity level, and recommend changes in these areas. They advocate for the use of a CVD risk screening tool in practice which includes assessing oral contraceptive risks, measuring weight and BP, asking about smoking status, and identifying history of migraine headaches and pregnancy complications. Redline and Foody [26] push the edge of practice by making a case for the inclusion of sleep disorders as a top 10 modifiable risk for CVD. The Robbins et al. [36] publication of the missed opportunities of BP and cholesterol screening also calls for systems change in the emerging healthcare system and medical home.
Synthesis of perspectives
Progress in raising awareness and promoting action to receive emergency cardiac care has been slow and disappointing. Targeted screening and risk identification are the foundation for prescribing preventive pharmacologic therapies. More data are needed to determine how to appropriately assess women of different age groups. There is also a need to re-evaluate both the Reynold's risk score and the Framingham risk score in young women, in whom the score traditionally underestimates their risk and hence their need for preventive interventions [16] . However, lifestyle prescription may be universally applied in patient-provider discussions of CVD prevention through engaging in salutary lifestyle habits such as the AHA's Life's Simple Seven, which includes health enhancing steps to get active, control cholesterol, eat better, manage BP, lose weight, reduce blood sugar and stop smoking [53] . Providers can play an important role in recommending lifestyle change, encouraging maintenance of behaviors or making referrals to initiate or maintain behaviors. The role of primary providers, mid-level practitioners and women's care providers in screening and primary prevention holds high potential to reduce the burden of CVD risks and disease in women. The importance of modification of lifestyle risk factors in addition to pharmacotherapy measures should be emphasized [17] . Clinicians may desire clinical measures and 'red flags' to identify women to target who would most benefit from prevention efforts and intervention.
Our knowledge of and guidelines for primary and secondary prevention and management of risk factors have not appreciably expanded as the latest published guidelines [6, 10] . To make progress in combating CVD in women, women need to be better represented in CVD prevention trials. For example, Melloni et al. [54] reported that women represented only 30% of patients enrolled in the clinical trials used to support the 2007 AHA guidelines for CVD prevention in women. Standardized reporting of trials should include racial/ethnic and sex subgroups to generate evidence to feed new insights into 'at risk' groups. To the list of traditional risk factors associated with CVD, Lee and Foody [55] add sleep disorders and sleep apnea. This past year, evidence has been added to heighten concern about CVD risks of women who are disadvantaged or who have poor psychosocial profiles. Previously, Leifheit-Limson et al. [56] reported in their study findings that acute myocardial infarction (AMI) patients with low social support at hospital presentation had worse outcomes throughout the first year after their AMI than did patients with high social support. They also had greater risk of angina, poorer disease-specific quality of life, poorer general mental functioning and more depressive symptoms. The relationship between social support at hospital presentation and outcomes did not vary over the first year of AMI recovery, except for angina; and the relationship between social support at hospital presentation and AMI outcomes was stronger for women than for men, with a significant social support-by-sex interaction observed for the outcomes of disease-specific quality of life, general physical functioning and depressive symptoms. Berra [34] and Galbraith et al. [39] provide discussion and further evidence to our growing awareness of the importance of socioeconomic factors and psychosocial profiles as intriguing targets of preventive intervention.
Our viewpoints
The guidelines for prevention of CVD in women provide important recommendations for screening and identification of women at risk or high risk for CVD. Appropriate medical and lifestyle therapies (i.e. behavior therapy coupled with pharmacologic therapy, when needed), referrals to nonphysician providers for education (e.g. nurse or dietitian) and regular follow-up visits to manage risks are essential. Community-based approaches (e.g. improving nutrition environment and physical space) are also needed for greater impact, given that most patients spend the majority of their time outside clinic walls.
Limitations
Limitations are clearly defined by the constrained boundaries of the search terms used to narrow and focus the review. It is possible that important articles and studies were inadvertently excluded from the review due to the search strategies employed. Expert opinions were not inherently 'evidence-based,' and, indeed, the experts often provided conflicting views. However, this review provides a provocative update and fuel for future practice and research.
CONCLUSION
So what has this past year provided that is new, innovative or significant to help us to improve primary and secondary prevention of CVD in women? From this review, certain implications are evident and recommendations for first next steps in research and practice are gleaned. It is clear that current strategies to prevent CVD are not sufficient. New techniques to add to the armamentarium of clinical and public health practice approaches are required. Follow-up strategies are needed that provide continual doses of effective lifestyle strategies that foster behavioral changes. More research is needed to explore the costs and effect on morbidity, mortality and health-related quality of life.
To identify and engage women early on in prevention and treatment of CVD, systems-level approaches using the electronic health record are needed. It is further recommended that healthcare providers prescribe lifestyle changes as earnestly and with as much clarity and expectation as they prescribe drugs and refer patients for support from other health professionals, support groups and so on. All levels and types of providers (including OB/GYN and women's health practices) should be utilized to engage patients in the work of CVD prevention and improved health. Modes and means of frequent contact and connection are recommended, including social media such as Twitter and Facebook.
